Effect of an extract of Ganoderma lucidum in men with lower urinary tract symptoms: A double-blind, placebo-controlled randomized and dose-ranging study

Asian Journal of Andrology

Volumn 10, Issue 4, 2008, Pages 651-658

  Noguchi, Masanori ^a   Kakuma, Tatsuyuki ^a   Tomiyasu, Katsuro ^a   Kurita, Yoshiko ^a   Kukihara, Hiroko ^a   Konishi, Fumiko ^b   Kumamoto, Shoichiro ^b   Shimizu, Kuniyoshi ^c   Kondo, Ryuichiro ^c   Matsuoka, Kei ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Chlorella Industry   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

Lower urinary tract symptoms; Outcome; Phytotherapy; Randomized trial

Indexed keywords

GANODERMA LUCIDUM EXTRACT; PLACEBO; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BLOOD PRESSURE; BLOOD TOXICITY; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ECHOGRAPHY; FATIGUE; GANODERMA LUCIDUM; HEART RATE; HUMAN; HYPERTENSION; INTERNATIONAL PROSTATE SYMPTOM SCORE; LIVER TOXICITY; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; NAUSEA; NEPHROTOXICITY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RECOMMENDED DRUG DOSE; REFERENCE VALUE; RESIDUAL URINE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; URINE FLOW RATE; VOLUNTEER;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUGS, CHINESE HERBAL; HUMANS; MALE; MIDDLE AGED; PHYTOTHERAPY; PILOT PROJECTS; PROSTATE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC HYPERPLASIA; REISHI; TREATMENT OUTCOME; URINARY BLADDER, OVERACTIVE; URINARY INCONTINENCE;

EID: 45749124428     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1111/j.1745-7262.2008.00336.x     Document Type: Article

References (20)

1. Lowe FC, Fagelman E. Phytotherapy in the treatment of benign prostatic hyperplasia: An update. Urology 1999; 53: 671-8.
2. Van Leeuwen JH, Castro R, Busse M, Memelmans BL. The placebo effect in the pharmacologic treatment of patients with lower urinary tract symptoms. Eur Urol 2006; 50: 440-53.
3. Liu J, Fujita R, Sato M, Shimizu K, Konishi F, Noda K, et al. The effect of strain, growth stage and cultivating condition of Ganoderma lucidum on 5α-reductase inhibition. J Wood Sci 2005; 51: 189-92.
4. Wasser SP, Weis AL. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: A modern perspective. Crit Rev Immunol 1999; 19: 65-96.
5. Yun TK. Update from Asia. Asian studies on cancer chemoprevention. Ann NY Acad Sci 1999; 889: 157-92.
6. Barry MJ, Fowler FJ Jr, O'Leary MP, Bruskewitz RC, Holtgrewe HL, Mebust WK, et al. The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. J Urol 1992; 148: 1549-57; discussion 1564.
7. Kirby RS. The clinical assessment of benign prostatic hyperplasia. Cancer 1992; 70: 284-90.
8. Liu J, Shimizu K, Konishi F, Noda K, Kumamoto S, Kondo R. Anti-androgenic activities of the triterpenoids fraction of Ganoderma lucidum. Food Chem 2007; 100: 1691-6.
9. The Finasteride Study Group. Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993; 22: 291-9.
10. Andersen JT, Ekman P, Wolf H, Beisland HO, Johansson JE, Kontturi M, et al. Can finasteride reverse the progress of benign prostatic hyperplasia? A two year placebo-controlled study. Urology 1995; 46: 631-7.
11. Boyle P, Gould AI, Roehrborn G. Prostate volume predicts outcome or treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 1996; 48: 398-405.
12. Hamdy PC, Chopin DK, Authie D. Prostate volume does not correlate with efficacy of treatment for mild to moderate benign prostatic hyperplasia using either finastride or phytotherapy. Proceedings of the Fourth International Consultation on BPH; 1997 July 2-5; Paris, Japan.
13. Bayne CW, Donnelly F, Ross F, Habib FK. Serenoa repens (Permixon®): a 5alpha-reductase types I and II inhibiter-new evidence in a coculture model of BPH. Prostate 1999; 40: 232-41.
14. Wang LG, Liu XM, Kreis W, Budman DR. Down-regulation of prostate-specific antigen expression by finasteride through inhibition of complex formation between androgen receptor and steroid receptor-binding consensus in the promoter region of the PSA gene in LNCaP cells. Cancer Res 1997; 57: 379-95.
15. Birch NC, Hurst G, Doyle PT. Serial residual volume in men with prostatic hyperplasia. Br J Urol 1992; 148: 1549-57.
16. Dreikorn K. The role of phytotherapy in treating lower urinary tract symptoms and benign prostatic hyperplasia. World J Urol 2002; 19: 426-35.
17. Chapple CR. Introduction and concluding remarks. Eur Urol 1999; 36 (Suppl 3): 1-6.
18. Ernst E. Harmless herbs? A review of the recent literature. Am J Med 1998; 104: 170-8.
19. Astin JA. Why patients use alternative medicine: Result of a national study. JAMA 1998; 279: 1548-53.
20. Speakman MJ. Who should be treated and how? Evidence based medicine in symptomatic BPH. Eur Urol 1999; 36 (Suppl 3): 40-51.